Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $586,160.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at approximately $11,351,794.37. This trade represents a 4.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jim Wassil also recently made the following trade(s):

• On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.22, for a total value of $689,760.00.
• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $83.66, for a total value of $669,280.00.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $72.10 on Tuesday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The firm’s fifty day moving average is $84.30 and its 200-day moving average is $94.91. The firm has a market cap of $9.28 billion, a P/E ratio of -15.67 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PCVX. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $147.50.

Institutional Investors Weigh In On Vaxcyte

Several large investors have recently added to or reduced their stakes in the business. Natixis Advisors LLC lifted its stake in Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after buying an additional 8,606 shares during the period. Diversified Trust Co bought a new stake in shares of Vaxcyte in the 4th quarter valued at $1,433,000. Lisanti Capital Growth LLC lifted its position in shares of Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after acquiring an additional 13,175 shares during the period. Curi RMB Capital LLC acquired a new position in shares of Vaxcyte during the 3rd quarter valued at $903,000. Finally, WCM Investment Management LLC boosted its stake in Vaxcyte by 52.6% during the third quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock worth $15,935,000 after acquiring an additional 48,543 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.